Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance

The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treate...

Full description

Bibliographic Details
Main Authors: Alfredo Tartarone, Rosa Lerose
Format: Article
Language:English
Published: SAGE Publishing 2015-10-01
Series:Therapeutic Advances in Respiratory Disease
Online Access:https://doi.org/10.1177/1753465815587820
id doaj-b7f0f9e41cf5456597b6e1347919fc9b
record_format Article
spelling doaj-b7f0f9e41cf5456597b6e1347919fc9b2020-11-25T03:28:28ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46581753-46662015-10-01910.1177/1753465815587820Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistanceAlfredo TartaroneRosa LeroseThe discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.https://doi.org/10.1177/1753465815587820
collection DOAJ
language English
format Article
sources DOAJ
author Alfredo Tartarone
Rosa Lerose
spellingShingle Alfredo Tartarone
Rosa Lerose
Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
Therapeutic Advances in Respiratory Disease
author_facet Alfredo Tartarone
Rosa Lerose
author_sort Alfredo Tartarone
title Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
title_short Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
title_full Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
title_fullStr Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
title_full_unstemmed Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
title_sort clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
publisher SAGE Publishing
series Therapeutic Advances in Respiratory Disease
issn 1753-4658
1753-4666
publishDate 2015-10-01
description The discovery of epidermal growth factor receptor activating mutations (EGFR Mut+) has determined a paradigm shift in the treatment of non-small cell lung cancer (NSCLC). In several phase III studies, patients with NSCLC EGFR Mut+ achieved a significantly better progression-free survival when treated with a first- (gefitinib, erlotinib) or second-generation (afatinib) EGFR tyrosine kinase inhibitor (TKI) compared with standard chemotherapy. However, despite these impressive results, most patients with NSCLC EGFR Mut+ develop acquired resistance to TKIs. This review will discuss both the mechanisms of resistance to TKIs and the therapeutic strategies to overcome resistance, including emerging data on third-generation TKIs.
url https://doi.org/10.1177/1753465815587820
work_keys_str_mv AT alfredotartarone clinicalapproachestotreatpatientswithnonsmallcelllungcancerandepidermalgrowthfactorreceptortyrosinekinaseinhibitoracquiredresistance
AT rosalerose clinicalapproachestotreatpatientswithnonsmallcelllungcancerandepidermalgrowthfactorreceptortyrosinekinaseinhibitoracquiredresistance
_version_ 1724584039246987264

Similar Items